Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace has received FDA Investigational Device Exemption for its RNS® System to study treatment of drug-resistant idiopathic generalized epilepsy (IGE) in patients aged 12 and older. The NAUTILUS study will be the first in the U.S. to evaluate brain-responsive neuromodulation for IGE treatment, starting patient enrollment in 2022. The RNS System aims to improve life quality by monitoring and responding to patients' unique brain patterns. Previously, it received Breakthrough Device Designation from the FDA for this condition.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will release its third-quarter 2021 financial results on November 10, 2021, after market close. Following the results, the company's management will host a conference call at 1:30 p.m. PT, available via dial-in or through a live webcast on their website. NeuroPace specializes in medical devices aimed at treating epilepsy, utilizing its innovative RNS System which provides personalized neuromodulation therapy to patients with drug-resistant seizures.
NeuroPace (Nasdaq: NPCE) announced on October 19, 2021, the appointment of Lisa Andrade to its Board of Directors, effective November 1, 2021. Andrade brings over 25 years of experience in the medtech sector and is currently the CEO of M33. She has held key positions at St. Jude Medical and possesses expertise in strategy, product development, and marketing. Additionally, Evan Norton is resigning from the board. Andrade expressed excitement about contributing to NeuroPace’s mission to transform epilepsy care with its RNS® System, approved for drug-resistant focal epilepsy.
MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced participation in three significant healthcare conferences. The schedule includes:
- Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 9:20 a.m. ET.
- Morgan Stanley Global Healthcare Conference on September 14, 2021, at 3:30 p.m. ET.
- Baird Global Healthcare Conference on September 15, 2021, at 2:35 p.m. ET.
Live audio will be available on the company’s website, with archives accessible for at least 90 days post-event.
NeuroPace, based in Mountain View, reported a 65% revenue increase to $12.6 million for Q2 2021. Initial implant revenues surged 100% to $9.2 million. The company received a $9.3 million grant from NIH's BRAIN Initiative to evaluate its RNS System for Lennox-Gastaut Syndrome. Despite increased revenues, operating expenses rose to $14 million, leading to a net loss of $8.5 million. NeuroPace forecasts a full-year revenue of approximately $47 million, a 14% growth year-over-year, but anticipates declining replacement implant revenues due to extended device battery life.
NeuroPace, Inc. (Nasdaq: NPCE) will report its financial results for Q2 2021 on August 12, 2021, after market close. A conference call with management will follow at 1:30 p.m. PT/4:30 p.m. ET, accessible by dialing (844) 955-2173 for domestic or (914) 987-7949 for international participants. NeuroPace specializes in innovative medical devices for epilepsy, with its RNS System being the only brain-responsive neuromodulation platform available, providing personalized treatment to patients with drug-resistant epilepsy.
NeuroPace has received a $9.3 million NIH grant through the BRAIN Initiative to evaluate its RNS® System for treating Lennox-Gastaut Syndrome (LGS), a severe childhood epilepsy. This Investigational Device Exemption (IDE) study is set to enroll patients in the second half of 2022. The study will be the first to assess neuromodulation in LGS patients and aims to provide insights into personalized treatment. The FDA must approve the study, with the possibility of a larger clinical trial following positive results.
NeuroPace, Inc. (NPCE) reported Q1 2021 financial results, showing total revenue of $11.2 million, a 12% increase from Q1 2020. Initial implant revenue reached $8.1 million, marking a 23% rise. The company successfully completed its IPO, raising approximately $105 million. Despite positive growth, net loss widened to $8.8 million, up from $6.7 million year-over-year. For 2021, total revenue guidance is set at $47 million, reflecting 14% growth. Replacement implant revenue is expected to decline by 16%.
NeuroPace, Inc. (Nasdaq: NPCE) will report its Q1 2021 financial results on June 3, 2021, before market open. A conference call will be held at 5:00 a.m. PT (8:00 a.m. ET) to discuss the results, with investors able to join by dialing (844) 955-2173 for domestic calls or (914) 987-7949 for international calls, using ID: 1485513. NeuroPace specializes in a brain-responsive neuromodulation platform aimed at treating epilepsy, offering a personalized approach to managing debilitating seizures.
NeuroPace, Inc. (Nasdaq: NPCE) successfully completed its initial public offering (IPO) on April 26, 2021, by closing the sale of 6,900,000 shares at $17.00 each. This offering included the full exercise of underwriters' options for 900,000 additional shares, resulting in gross proceeds of approximately $117.3 million. The company focuses on innovative products for epilepsy treatment, with its RNS System being the first brain-responsive platform available. The stock began trading on April 22, 2021.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
What is NeuroPace, Inc. known for?
What medical condition does the RNS® System primarily target?
Where is NeuroPace, Inc. based?
How does the RNS® System work?
Who are the primary customers for the RNS® System?
What recent achievements has NeuroPace made?
How does NeuroPace generate revenue?
Can the RNS® System treat conditions other than epilepsy?
What makes the RNS® System unique?
Who can be contacted for investor-related inquiries at NeuroPace?
